Journal of Clinical Microbiology, April 1999, p. 1178-1181, Vol. 37, No. 4
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Laboratoire de Santé Publique du
Québec,
Received 20 July 1998/Returned for modification 16 October
1998/Accepted 11 December 1998
In a context of worldwide emergence of resistance among
Streptococcus pneumoniae strains, early detection of
strains with decreased susceptibility to The emergence of resistance to
Isolates were sent to our laboratory for susceptibility testing or as
part of a multicenter surveillance study of invasive S. pneumoniae infections in the province of Quebec (17).
Between January 1995 and December 1996, strains (n = 1,116) were isolated from normally sterile body fluids (63%) and
respiratory tract sources (37%).
Susceptibility methods were performed as outlined by the NCCLS
(22, 23). Disk diffusion tests were performed on
Mueller-Hinton agar supplemented with 5% defibrinated sheep blood, and
test samples were incubated for 20 to 24 h at 35°C in a 5 to 7%
CO2 atmosphere. Oxacillin disks were purchased from Oxoid
(Unipath, Ontario, Canada). Broth microdilution tests were carried out
with an inoculum prepared from an overnight growth on blood agar plates
and adjusted to achieve approximately 5 × 105 CFU/ml.
MICs were recorded after 20 to 24 h of incubation at 35°C in
ambient air. Twofold dilutions of benzylpenicillin (32 to 0.03 µg/ml)
of ceftriaxone (32 to 0.03 µg/ml) were performed with cation-adjusted
Mueller-Hinton broth supplemented with 2 to 5% lysed horse blood.
Antimicrobial powders were purchased from Sigma Chemical Co. (St.
Louis, Mo.). S. pneumoniae ATCC 49619 was used as a control
throughout the investigation and included with each batch of diffusion
and microdilution tests. Results were interpreted according to NCCLS recommendations.
Figure 1 is a scattergram comparing
oxacillin zone diameters to penicillin MICs for 1,116 strains. As
expected, all strains (n = 592) showing a zone size of
![]()
ABSTRACT
Top
Abstract
Text
References
-lactam antibiotics is
important for clinicians. If the 1-µg oxacillin disk diffusion test
is used as described by the National Committee for Clinical Laboratory Standards, no interpretation is available for strains showing zone
sizes of
19 mm, and there is presently no disk diffusion test
available for screening cephalosporin resistance. The zones obtained by
the diffusion method by using the 1-µg oxacillin disk were compared
with penicillin MICs for 1,116 clinical strains and with ceftriaxone
MICs for 695 of these strains. Among the 342 strains with growth up to
the 1-µg oxacillin disk margin, none were susceptible (MIC,
0.06
µg/ml), 62 had intermediate resistance (MIC, 0.12 to 1.0 µg/ml),
and 280 were resistant (MIC,
2.0 µg/ml) to penicillin. For
ceftriaxone, among 98 strains with no zone of inhibition in response to
oxacillin, 68 had intermediate resistance (MIC, 1.0 µg/ml), and 22 were resistant (MIC,
2.0 µg/ml). To optimize the use of the disk
diffusion method, we propose that the absence of a zone of inhibition
around the 1-µg oxacillin disk be regarded as an indicator of
nonsusceptibility to penicillin and ceftriaxone and recommend that such
strains be reported as nonsusceptible to these antimicrobial agents,
pending the results of a MIC quantitation method.
![]()
TEXT
Top
Abstract
Text
References
-lactam antibiotics in clinical isolates of Streptococcus
pneumoniae has been reported throughout the world with increasing
frequency (1, 8, 11, 12, 21, 25, 31). Because of the
consequences of
-lactam resistance to the clinical response to
antimicrobial therapy and the possible need to modify such a therapy
based on susceptibility results, early detection of strains with
decreased susceptibility to these antibiotics is important
(20, 24). The diffusion method with a 1-µg oxacillin
disk is currently recommended by the National Committee for Clinical
Laboratory Standards (NCCLS) (22, 23) as an effective
screening method for the detection of penicillin-resistant pneumococci
and is commonly used by clinical laboratories. Although many studies
have been done with disks containing ceftriaxone, cefotaxime, cefixime,
ceftizoxime, cefuroxime, and loracarbef, there is presently no disk
diffusion test available for the screening of cephalosporin resistance
(2, 4, 5, 14, 15, 27). The recommended interpretative zone
criteria for the detection of penicillin susceptibility with the 1-µg
oxacillin disk is a zone size of
20 mm. No interpretation is
available for zone sizes of
19 mm, because strains of pneumococci
with this characteristic can be either sensitive, intermediately
resistant, or resistant to penicillin (30). In this
situation, determination of the strain susceptibility to penicillin by
a quantitative method is indicated. The 1-µg oxacillin test is
regarded as very sensitive for detection of penicillin resistance, but
of low specificity. This study reports observations concerning the
relationship between the absence of a growth inhibition zone around the
1-µg oxacillin disk and the susceptibility of S. pneumoniae to penicillin and ceftriaxone. It also reassesses the
value of the oxacillin disk test, not only as a predictor of penicillin
susceptibility, but also as a tool to rapidly detect decreased
susceptibility to penicillin and ceftriaxone.
20 mm were found susceptible (MIC,
0.06 µg/ml) to penicillin by
the microdilution method. Among a total of 645 strains found
susceptible by microdilution, 53 (8.2%) yielded oxacillin zone sizes
of
19 mm and would be misclassified as nonsusceptible on the basis of
the disk test. For the non-penicillin-susceptible strains (MIC,
0.12
µg/ml), all 189 intermediately resistant (MIC, 0.1 to 1.0 µg/ml)
and all 282 resistant (MIC,
2.0 µg/ml) strains had oxacillin zone
diameters of
19 mm. However, more interestingly, among the 342 strains with growth up to the disk margin (zone diameter = disk
diameter = 6 mm), none were susceptible to penicillin: 62 and 280, respectively, were intermediately resistant and resistant to penicillin
(Table 1). The absence of a zone of
growth inhibition around the oxacillin disk had positive predictive
values of 82% for resistance to penicillin (MIC,
2 µg/ml) and
100% for nonsusceptibility (MIC,
0.12 µg/ml). In Quebec, the
prevalence of penicillin resistance found in our prospective
surveillance program in 1996 was 6.9%, while the prevalence of
nonsusceptibility was 9.8% (17). Taking into account these prevalence rates, the new positive predictive values for resistance as
well as nonsusceptibility to penicillin were 87.6 and 100%, respectively.

View larger version (12K):
[in a new window]
FIG. 1.
Scattergram comparing penicillin MICs to zones of
inhibition around a 1-µg oxacillin disk. A total of 1,116 S. pneumoniae isolates were tested.
TABLE 1.
Distribution of 1,116 strains by MICs of penicillin and
growth inhibition zone diameter around 1-µg oxacillin disk
Among the 1,116 strains tested by disk diffusion, 695 were also tested
for ceftriaxone susceptibility by broth microdilution. Figure
2 is a scattergram comparing oxacillin
zone diameters with ceftriaxone MICs. Among the 98 strains with no zone
diameter of inhibition in response to oxacillin, 68 (69.4%) were
intermediately resistant (MIC, 1 µg/ml) and 22 (22.4%) were
resistant (MIC,
2.0 µg/ml) to ceftriaxone. The positive predictive
value was 85%, taking into account the observed prevalence of
nonsusceptibility to ceftriaxone (MIC,
1.0 µg/ml) established at
7.1% in our surveillance program. We also observed that among strains
tested with penicillin and ceftriaxone, 86 were found resistant (MIC,
2.0 µg/ml) to penicillin, and only 1 of them was susceptible to
ceftriaxone (MIC, 0.5 µg/ml). The ceftriaxone MICs for 63 and 22 of
the remaining strains, respectively, were 1.0 (intermediate resistance)
and 2.0 µg/ml (resistant).
|
All strains were tested along with the quality control strain, S. pneumoniae ATCC 49619 (23). Results obtained with this strain were always within the recommended MIC limits of penicillin (n = 147) and ceftriaxone (n = 104). For the disk diffusion method, concordance was 98%; in two occasions among 96 tests, the zone diameters were out of the expected range. Clinical strains belonging to these two batches were retested.
In Quebec, during the last 10 years, the prevalence of pneumococci
nonsusceptible to penicillin (MIC,
0.12 µg/ml) rose from 1.3% to
9.8%, and the resistance rate (strains for which MICs were
2.0
µg/ml) increased from 0% to 6.9% (16, 17). The impact of
this resistance on the treatment of severe pneumococcal infections is
serious (8, 11, 20, 21). In the microbiology laboratories, the disk diffusion method with the 1-µg oxacillin disk is largely used in the screening of penicillin nonsusceptibility. Presently, there
is no disk diffusion method accepted for the detection of broad-spectrum cephalosporin resistance, because minor error rates of
more than 15% have been reported (18) for cefotaxime and ceftriaxone. As published previously (10, 18, 30) and
confirmed by this study, a zone of growth inhibition of 20 mm or more
around the 1-µg oxacillin disk is always predictive of susceptibility to penicillin. Similarly to what was previously reported by Doern et
al. (10) and Jorgensen et al. (18), we observed
some strains fully penicillin sensitive with an oxacillin zone size of
19 mm. The limitations of the oxacillin diffusion test are well
documented by the NCCLS. Unfortunately, MIC determinations for strains
showing zone sizes of
19 mm introduce a delay of at least 1 day in
reporting the final result. For laboratories with sufficient technical
resources, Doern et al. (10) recently recommended that MIC
tests be performed directly, at least for strains isolated from
cerebrospinal fluid. The NCCLS recommends testing of pneumococcal
isolates from blood and the central nervous system (CNS) by using a MIC
method, since reliable disk diffusion tests with agents such as
ceftriaxone and cefotaxime do not yet exist (23).
Unfortunately, the necessary technical resources are not always
available on-site. Our study shows that the absence of a zone around
the 1-µg oxacillin disk is highly predictive of penicillin and
ceftriaxone nonsusceptibility. The results obtained by Doern et al.
(10) and Barry et al. (4) were similar to ours.
These studies presented scattergrams comparing MICs of penicillin or
cefixime to zone inhibitions around a 1-µg oxacillin disk and showed
that 99 and 98% of pneumococci with no zone of inhibition in response
to oxacillin were nonsusceptible to penicillin, and 99% of them were
also nonsusceptible to cefixime. The oxacillin disk test was also
useful in predicting nonsusceptibility to cephalosporins when strains
grew up to the margin of the disk. Unfortunately, discrimination
between intermediate susceptibility and resistance cannot be achieved
with enough confidence to be of any use, even with other
-lactam disks.
Penicillin remains the antibiotic of choice for treatment of infections caused by susceptible strains of S. pneumoniae. A high dosage is recommended for treatment of meningitis and other infections of the CNS. Penicillin at a higher dosage is recommended for pneumococci with intermediate susceptibility to penicillin in non-CNS infections, whereas for meningitis, other antimicrobial agents should be used, because many reports of penicillin failure with even moderately resistant strains have been published. Obviously, penicillin is not an option for any CNS infection with pneumococci showing resistance to penicillin. For the treatment of severe non-CNS infections with resistant strains, many experts recommend another antimicrobial agent (6, 7, 9, 13, 19, 25, 26).
Studies have shown that an increase in MICs of penicillin is usually
accompanied by increases in MICs of other
-lactams (3, 28,
29). The extremely high rate of decreased ceftriaxone susceptibility among our penicillin-resistant strains is
disturbing, because this antimicrobial agent or cefotaxime is
part of the antimicrobial regimen for the treatment of meningitis
caused by these strains.
As recommended by the NCCLS, MIC determinations are indicated for
strains with a zone inhibition of
19 mm with oxacillin. For
pneumococcal meningitis, immediate MIC testing is certainly a
legitimate option. However, for the majority of other infections caused
by S. pneumoniae, the 1-µg oxacillin disk screening test, due mainly to its simplicity and cost-effectiveness, remains an attractive method. We propose that strains with growth up to the margin of the oxacillin disk be reported as nonsusceptible to penicillin and ceftriaxone pending MIC results. This would be of
particular interest to small institutions which have to rely on
reference laboratories for MIC testing, further delaying the presentation of final results. Performance of MIC testing of such strains should be dictated by the severity of patient infection. In
hospitals with a very high prevalence of penicillin resistance, immediate MIC testing of penicillin and broad-spectrum cephalosporins, by the dilution or E-test method, for all or the majority of
pneumococci is an option to be considered.
| |
ACKNOWLEDGMENTS |
|---|
We thank Martial Demers and François Robillard for technical assistance. We are grateful to Gilles Delage for helpful comments on the manuscript. Finally, we thank Lucie Carrière for secretarial assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Santé Publique du Québec, 20045 Chemin Sainte-Marie, Sainte-Anne-de-Bellevue (Québec) Canada H9X 3R5. Phone: (514) 457-2070. Fax: (514) 457-6346. E-mail: ljette{at}lspq.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Baquero, F.
1995.
Pneumococcal resistance to -lactam antibiotics: a global geographic overview.
Microb. Drug Resist.
1:115-120.
[Medline] |
| 2. | Barry, A. L., S. D. Brown, and W. J. Novick. 1995. Criteria for testing the susceptibility of Streptococcus pneumoniae to cefotaxime and its desacetyl metabolite using 1 µg or 30 µg cefotaxime disks. Eur. J. Clin. Microbiol. Infect. Dis. 14:724-726[Medline]. |
| 3. | Barry, A. L., S. D. Brown, and W. J. Novik. 1995. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 39:2193-2196[Abstract]. |
| 4. | Barry, A. L., and P. C. Fuchs. 1995. Methods for predicting susceptibility of Streptococcus pneumoniae to cefixime. J. Clin. Microbiol. 33:1031-1033[Abstract]. |
| 5. | Barry, A. L., and P. C. Fuchs. 1996. Surrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniae. J. Clin. Microbiol. 34:2609-2612[Abstract]. |
| 6. | Bartlett, J. G., R. F. Breiman, L. A. Mandel, and T. M. File. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838[Medline]. |
| 7. | Bradley, J. S., and W. M. Scheld. 1997. The challenge of penicillin-resistant Streptococcus pneumoniae meningitidis: current antibiotic therapy in the 1990s. Clin. Infect. Dis. 24:S213-S221. |
| 8. | Butler, J. C., J. Hofmann, M. S. Cetron, J. A. Elliott, R. R. Facklam, R. F. Breiman, and the Pneumococcal Sentinel Surveillance Working Group. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention pneumococcal sentinel surveillance system. J. Infect. Dis. 174:986-993[Medline]. |
| 9. |
Committee on Infectious Diseases.
1997.
Therapy for children with invasive pneumococcal infections.
Pediatrics
99:289-299 |
| 10. | Doern, G. V., A. B. Brueggemann, and G. Pierce. 1997. Assessment of the oxacillin disk screening test for determining penicillin resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 16:311-313[Medline]. |
| 11. | Doern, G. V., A. B. Brueggemann, H. Preston Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213[Abstract]. |
| 12. | Feldman, C., and K. Klugman. 1997. Pneumococcal infections. Curr. Opin. Infect. Dis. 10:109-115. |
| 13. |
Friedland, I. R., and G. H. McCracken, Jr.
1994.
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N. Engl. J. Med.
331:377-382 |
| 14. |
Friedland, I. R.,
S. Shelton, and G. H. McCracken, Jr.
1993.
Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test.
J. Clin. Microbiol.
31:1619-1621 |
| 15. |
Goldstein, F. W.,
M. D. Kitzis, and J. F. Acard.
1994.
Screening for extended-spectrum cephalosporin resistance in Streptococcus pneumoniae.
J. Antimicrob. Chemother.
34:1076-1077 |
| 16. |
Jetté, L. P.,
F. Lamothe, and The Pneumococcus Study Group.
1989.
Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics.
J. Clin. Microbiol.
27:1-5 |
| 17. | Jetté, L. P., L. Ringuette, and The Pneumococcus Study Group. 1997. Surveillance program of invasive Streptococcus pneumoniae strains in the province of Québec, abstr. E-116, p. 134. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 18. |
Jorgensen, J. H.,
J. M. Swenson,
F. C. Tenover,
M. J. Ferraro,
J. A. Hindler, and P. R. Murray.
1994.
Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae.
J. Clin. Microbiol.
32:2448-2459 |
| 19. | Klugman, K. P. 1996. Epidemiology, control, and treatment of multiresistant pneumococci. Drugs 52:42-46. |
| 20. |
Koornhof, H. J., and K. P. Klugman.
1997.
Evolution of extended spectrum cephalosporin resistance in the pneumococcus.
J. Antimicrob. Chemother.
39:837-842 |
| 21. | Lovgren, M., J. S. Spika, and J. A. Talbot. 1998. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. Can. Med. Assoc. J. 158:327-331[Abstract]. |
| 22. | National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6 National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 23. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4 National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 24. | Pacheco, T. R., C. K. Cooper, D. J. Hardy, R. F. Betts, and W. Bonnez. 1997. Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitidis. Am. J. Med. 102:303-305[Medline]. |
| 25. |
Pallares, R.,
J. Linares,
M. Vadillo,
C. Cabellos,
F. Manresa,
P. F. Viladrich,
R. Martin, and F. Gudiol.
1995.
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N. Engl. J. Med.
333:474-479 |
| 26. |
Quagliarello, V. J., and W. M. Scheld.
1997.
Treatment of bacterial meningitidis.
N. Engl. J. Med.
336:708-716 |
| 27. | Schutze, G. E., M. J. Lewno, and E. O. Mason, Jr. 1997. Use of ceftizoxime screening for the detection of cephalosporin-resistant pneumococci. Diagn. Microbiol. Infect. Dis. 27:99-101[Medline]. |
| 28. |
Sifaoui, F.,
M.-D. Kitzis, and L. Gutmann.
1996.
In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral -lactam antibiotics is associated with alterations of PBP2x.
Antimicrob. Agents Chemother.
40:152-156[Abstract].
|
| 29. |
Spangler, S. K.,
M. R. Jacobs, and P. C. Appelbaum.
1994.
Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.
Antimicrob. Agents Chemother.
38:898-900 |
| 30. |
Swenson, J. M.,
B. C. Hill, and C. Thornsberry.
1986.
Screening pneumococci for penicillin resistance.
J. Clin. Microbiol.
24:749-752 |
| 31. | Tomasz, A. 1997. Antibiotic resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 24:S85-S88. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|